Sphera Funds Management LTD Has Cut Sarepta Therapeutics (Call) (SRPT) Stake By $10.49 Million; Agco Has 0.81 Sentiment

February 23, 2018 - By Peter Erickson

Sphera Funds Management Ltd decreased Sarepta Therapeutics Inc (Call) (SRPT) stake by 60.84% reported in 2017Q3 SEC filing. Sphera Funds Management Ltd sold 233,047 shares as Sarepta Therapeutics Inc (Call) (SRPT)’s stock rose 22.49%. The Sphera Funds Management Ltd holds 150,000 shares with $6.80 million value, down from 383,047 last quarter. Sarepta Therapeutics Inc (Call) now has $4.09 billion valuation. The stock increased 0.37% or $0.23 during the last trading session, reaching $63.24. About 96,640 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since February 23, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The company has market cap of $5.44 billion. The firm offers tractors, including high horsepower tractors that are used on larger farms, primarily for row crop production; utility tractors for small- and medium-sized farms, as well as for dairy, livestock, orchards, and vineyards; and compact tractors for small farms, specialty agricultural industries, landscaping, and residential uses. It has a 29.5 P/E ratio. It also provides combines that are used in harvesting grain crops; and application equipment, including self-propelled, three- and four-wheeled vehicles and related equipment for use in the application of liquid and dry fertilizers and crop protection chemicals, as well as for after crops emerge from the ground.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on March, 1 after the close. They expect $-0.35 EPS, up 77.85% or $1.23 from last year’s $-1.58 per share. After $-0.78 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -55.13% EPS growth.

Since October 3, 2017, it had 0 insider buys, and 1 insider sale for $575,000 activity. Ruff Shamim sold 11,500 shares worth $575,000.

Investors sentiment increased to 2.88 in Q3 2017. Its up 1.36, from 1.52 in 2017Q2. It increased, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Geode Mgmt Ltd Liability Corp has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 2,471 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Bnp Paribas Arbitrage holds 6,792 shares or 0% of its portfolio. Marshall Wace Llp holds 0.06% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 27,813 shares. Sg Americas Securities Llc owns 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 8,300 shares. Asset Mgmt, a New York-based fund reported 8,089 shares. 1.45 million are held by Deutsche Commercial Bank Ag. Fred Alger Incorporated stated it has 0.3% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Eam owns 0.37% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 61,155 shares. Dupont Capital Mgmt holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 12,722 shares. Hightower Advsrs Limited Liability Company reported 69,596 shares. Oppenheimer & Com holds 33,592 shares. Macquarie Grp Incorporated, a Australia-based fund reported 33,000 shares. Quantbot Tech Lp accumulated 819 shares. Samlyn Capital Lc holds 0.16% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 137,867 shares.

Sphera Funds Management Ltd increased Biomarin Pharmaceutical Inc (NASDAQ:BMRN) stake by 10,000 shares to 85,000 valued at $7.91M in 2017Q3. It also upped Vistagen Therapeutics Inc (VSTA) stake by 514,286 shares and now owns 1.06M shares. Celgene Corp (NASDAQ:CELG) was raised too.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 81% are positive. Sarepta Therapeutics had 103 analyst reports since August 5, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of SRPT in report on Thursday, September 7 with “Outperform” rating. Piper Jaffray downgraded the shares of SRPT in report on Friday, January 15 to “Neutral” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Wednesday, September 6 by Needham. The company was maintained on Wednesday, June 21 by RBC Capital Markets. Leerink Swann upgraded the shares of SRPT in report on Thursday, March 2 to “Outperform” rating. The firm has “Equal-Weight” rating given on Wednesday, January 4 by Morgan Stanley. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Neutral” rating given on Tuesday, September 1 by SunTrust. As per Wednesday, January 3, the company rating was initiated by Janney Capital. Roth Capital maintained the shares of SRPT in report on Wednesday, August 26 with “Buy” rating. The firm has “Overweight” rating given on Monday, October 2 by Morgan Stanley.

Since January 1, 0001, it had 0 insider buys, and 2 sales for $223,722 activity.

Zuckerman Investment Group Llc holds 4.95% of its portfolio in AGCO Corporation for 273,512 shares. Southernsun Asset Management Llc owns 2.37 million shares or 4.29% of their US portfolio. Moreover, Blue Harbour Group L.P. has 4.1% invested in the company for 1.54 million shares. The Massachusetts-based Schwerin Boyle Capital Management Inc has invested 3.44% in the stock. Odey Asset Management Group Ltd, a United Kingdom-based fund reported 474,565 shares.

The stock increased 1.29% or $0.87 during the last trading session, reaching $68.43. About 18,717 shares traded. AGCO Corporation (AGCO) has risen 25.79% since February 23, 2017 and is uptrending. It has outperformed by 9.09% the S&P500.

Analysts await AGCO Corporation (NYSE:AGCO) to report earnings on April, 27. They expect $0.12 earnings per share, up 700.00% or $0.14 from last year’s $-0.02 per share. AGCO’s profit will be $9.55M for 142.56 P/E if the $0.12 EPS becomes a reality. After $1.10 actual earnings per share reported by AGCO Corporation for the previous quarter, Wall Street now forecasts -89.09% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>